Cell therapy for diabetes: New data, approval, buyout; GLP-1 race in weight loss reaches new stage; FDA finally approves BioMarin’s gene therapy; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.